Nicola Minerva

1.8k total citations · 1 hit paper
18 papers, 1.3k citations indexed

About

Nicola Minerva is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Nicola Minerva has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 15 papers in Epidemiology and 2 papers in Infectious Diseases. Recurrent topics in Nicola Minerva's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (12 papers) and Liver Disease Diagnosis and Treatment (11 papers). Nicola Minerva is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (12 papers) and Liver Disease Diagnosis and Treatment (11 papers). Nicola Minerva collaborates with scholars based in Italy, United States and Brazil. Nicola Minerva's co-authors include Alessandra Mangia, Donato Bacca, Vito Carretta, Rosanna Santoro, Angelo Andriulli, Mario Romano, Gaetano Scotto, Giovanni Ricci, F. Vinelli and Fulvio Spirito and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Nicola Minerva

18 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3

2005 608 citations Alessandra Mangia, Rosanna Santoro et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Nicola Minerva

Since Specialization

Citations

This map shows the geographic impact of Nicola Minerva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Minerva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Minerva more than expected).

Fields of papers citing papers by Nicola Minerva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Minerva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Minerva. The network helps show where Nicola Minerva may publish in the future.

Co-authorship network of co-authors of Nicola Minerva

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Minerva. A scholar is included among the top collaborators of Nicola Minerva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Minerva. Nicola Minerva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	THE POREM BIO-ACTIVATOR AS A SOLUTION FOR DEGRADED SOILS: RESULTS OF FIRST ITALIAN TRIAL 2021 ·Environmental Engineering and Management Journal ·(unknown), E. Salernitano, (unknown), (unknown), Enrico Leoni, Giuseppe Magnani, (unknown), (unknown), (unknown), Federica Fontana, Nicola Minerva	1
2	Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? 2020 ·World Journal of Clinical Cases ·Alessandra Mangia, Giovanni Cenderello, Gabriella Verucchi, Alessia Ciancio, Andrea Fontana, Valeria Piazzolla, Nicola Minerva, Maria Maddalena Squillante, Massimiliano Copetti	15
3	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis 2018 ·PLoS ONE ·Alessandra Mangia, (unknown), Giovanni Cenderello, Domenico Potenza, Michele Mazzola, Giulio De Stefano, N. Terreni, Massimiliano Copetti, Nicola Minerva, (unknown), Donato Bacca, Vincenzo Ostilio Palmieri, Fernando Sogari, Rosanna Santoro	3
4	Hepatitis C and immigration: a multicentre study. 2016 ·PubMed ·Gaetano Scotto, Orlando Armignacco, Giulio Starnini, Ruggiero Francavilla, Giuseppe Foti, V. Portelli, (unknown), Nicola Minerva, Vito Carretta, Lorenzo Lo Muzio, Vincenzina Fazio	3
5	Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia 2014 ·Digestive and Liver Disease ·A. Iacobellis, Raffaele Cozzolongo, Nicola Minerva, Maria Rosa Valvano, Grazia Anna Niro, Rosanna Fontana, Orazio Palmieri, A Ippolito, Angelo Andriulli	1
6	Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience 2014 ·PLoS ONE ·Alessandra Mangia, Giovanni Cenderello, A. Orlandini, Valeria Piazzolla, A. Picciotto, Massimo Zuin, Alessia Ciancio, Giuseppina Brancaccio, (unknown), Vito Carretta, Anna Linda Zignego, Nicola Minerva, Gaetano Brindicci, Massimo Marignani, Gianluca Svegliati‐Baroni, Gaetano Bertino, (unknown), Leonardo Mottola, Maria Ripoli, Mario Pirisi	7
7	Interleukin‐28B genetic variants in untreated Italian HCV‐infected patients: a multicentre study 2014 ·Liver International ·Leonardo Mottola, Giovanni Cenderello, Valeria Piazzolla, (unknown), Vito Carretta, (unknown), Giuseppina Brancaccio, Rosalba Minisini, Massimo Zuin, N. Terreni, Monica Monti, Alberto Colombo, L. Nosotti, Nicola Minerva, (unknown), Alba Kostandini, (unknown), Maurizio Russello, Rosanna Santoro, Alessandra Mangia	4
8	Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring 2011 ·Hepatology ·Alessandra Mangia, Alexander Thompson, Rosanna Santoro, Valeria Piazzolla, Massimiliano Copetti, Nicola Minerva, D. Petruzzellis, Leonardo Mottola, Donato Bacca, John G. McHutchison	50
9	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3 2010 ·Journal of Hepatology ·Alessandra Mangia, (unknown), Giuseppe Montalto, Leonardo Mottola, Valeria Piazzolla, Nicola Minerva, Adriano Pellicelli, Giovanni Ricci, (unknown), Vito Carretta, Gaetano Scotto, Donato Bacca, B.E. Annicchiarico, Mario Romano, Maurizio Russello, Giorgio Barbarini, (unknown), Angelo Andriulli	18
10	An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response 2010 ·Gastroenterology ·Alessandra Mangia, Alexander Thompson, Rosanna Santoro, Valeria Piazzolla, Hans L. Tillmann, Keyur Patel, Kevin V. Shianna, Leonardo Mottola, D. Petruzzellis, Donato Bacca, Vito Carretta, Nicola Minerva, David B. Goldstein, John G. McHutchison	250
11	Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection # 2008 ·Hepatology ·Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, (unknown), Fernando Sogari, Gaetano Scotto, F. Vinelli, Giovanni Ricci, Mario Romano, Vito Carretta, D. Petruzzellis, Angelo Andriulli	46
12	Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial 2007 ·Hepatology ·Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Giovanni Ricci, Vito Carretta, F. Vinelli, Gaetano Scotto, Giuseppe Montalto, Mario Romano, Giuseppe Cristofaro, Leonardo Mottola, Fulvio Spirito, Angelo Andriulli	181
13	A case of vacuolar myopathy during the course of chronic hepatitis C. 2006 ·PubMed ·Stefano Zoccolella, Luigi Serlenga, (unknown), (unknown), Nicola Minerva, (unknown), Antonio Toscano, Paolo Lamberti	3
14	Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 breakdown → 2005 ·New England Journal of Medicine ·Alessandra Mangia, Rosanna Santoro, Nicola Minerva, Giovanni Ricci, Vito Carretta, Marcello Persico, F. Vinelli, Gaetano Scotto, Donato Bacca, Mauro Annese, Mario Romano, F Zechini, Fernando Sogari, Fulvio Spirito, Angelo Andriulli	608
15	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis 2002 ·Journal of Hepatology ·Alessandra Mangia, Rosanna Santoro, (unknown), Gioacchino Leandro, Nicola Minerva, Mauro Annese, Donato Bacca, Fulvio Spirito, Vito Carretta, (unknown), (unknown), Angelo Andriulli	17
16	A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis 2002 ·Journal of Hepatology ·Alessandra Mangia, Giovanni Ricci, Nicola Minerva, Marcello Persico, Vito Carretta, Donato Bacca, (unknown), (unknown), Vincenzo Guadagnino, Giovanni Di Maio, Angelo Andriulli	1
17	A Randomized Trial of Amantadine and Interferon Versus Interferon Alone As Initial Treatment for Chronic Hepatitis C 2001 ·Hepatology ·Alessandra Mangia, Nicola Minerva, Mauro Annese, Gioacchino Leandro, M Villani, Rosanna Santoro, Vito Carretta, Donato Bacca, (unknown), Michele Bisceglia, (unknown), (unknown), Angelo Andriulli	45
18	Efficacy of 5 MU of interferon in combination with ribavirin for naıve patients with chronic hepatitis C virus: a randomized controlled trial 2001 ·Journal of Hepatology ·Alessandra Mangia, M Villani, Nicola Minerva, Gioacchino Leandro, Donato Bacca, (unknown), Vito Carretta, (unknown), (unknown), (unknown), Angelo Andriulli	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact